Christopher Morabito insider trades: Astria Therapeutics (ATXS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | ATXS | ↓ Sell | 10,000 | $13.59 | $136K | Direct | Apr 3, 2024 (2d) |
| Jan 29, 2024 | ATXS | ↓ Sell | 10,000 | $11.14 | $111K | Direct | Jan 30, 2024 (1d) |
| Jun 28, 2021 | FULC | ↑ Buy | 1,100 | $9.16 | $10K | Direct | Jun 29, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christopher Morabito's insider trades
Christopher Morabito is Chief Medical Officer at Astria Therapeutics (ATXS). Since Jun 28, 2021, Christopher has reported 1 open-market purchase worth $10K and 2 sales worth $247K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATXS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.